ServicenavigationHauptnavigationTrailKarteikarten


Forschungsstelle
INNOSUISSE
Projektnummer
13939.1;8 PFLS-LS
Projekttitel
Generation of a genetically characterized and improved CHO cell-based GMP production platform
Projekttitel Englisch
Generation of a genetically characterized and improved CHO cell-based GMP production platform

Texte zu diesem Projekt

 DeutschFranzösischItalienischEnglisch
Kurzbeschreibung
-
Anzeigen
-
Anzeigen
Abstract
-
Anzeigen
-
Anzeigen

Erfasste Texte


KategorieText
Kurzbeschreibung
(Englisch)
Generation of a genetically characterized and improved CHO cell-based GMP production platform
Kurzbeschreibung
(Französisch)
Generation of a genetically characterized and improved CHO cell-based GMP production platform
Abstract
(Englisch)
We propose to devise a CHO cell-based platform with a fully sequenced annotated genome, and to engineer it to facilitate the identification of new protein therapeutics, to decrease production costs and to improve the quality and safety of therapeutic proteins. Our scientific aims are: i) to complete the sequencing and annotate the CHO cell genome, ii) to develop a more efficient gene transfer process for improved therapeutic protein expression based on the genome sequence, and iii) to establish a process to characterize the genome of therapeutic-producing CHO cell clones, to provide better characterized therapeutic proteins and to facilitate regulatory approval.
Abstract
(Französisch)
We propose to devise a CHO cell-based platform with a fully sequenced annotated genome, and to engineer it to facilitate the identification of new protein therapeutics, to decrease production costs and to improve the quality and safety of therapeutic proteins. Our scientific aims are: i) to complete the sequencing and annotate the CHO cell genome, ii) to develop a more efficient gene transfer process for improved therapeutic protein expression based on the genome sequence, and iii) to establish a process to characterize the genome of therapeutic-producing CHO cell clones, to provide better characterized therapeutic proteins and to facilitate regulatory approval.